CN1326841C - 具有内皮素拮抗剂活性的芳烷烃－磺胺类化合物 - Google Patents

具有内皮素拮抗剂活性的芳烷烃－磺胺类化合物 Download PDF

Info

Publication number
CN1326841C
CN1326841C CNB01815896XA CN01815896A CN1326841C CN 1326841 C CN1326841 C CN 1326841C CN B01815896X A CNB01815896X A CN B01815896XA CN 01815896 A CN01815896 A CN 01815896A CN 1326841 C CN1326841 C CN 1326841C
Authority
CN
China
Prior art keywords
compound
molecular formula
phenyl
acid
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB01815896XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1633418A (zh
Inventor
托马斯·韦勒
马丁·博利
克里斯托夫·博斯
马丁内·克洛泽尔
瓦尔特·菲施利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1633418A publication Critical patent/CN1633418A/zh
Application granted granted Critical
Publication of CN1326841C publication Critical patent/CN1326841C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB01815896XA 2000-09-25 2001-08-28 具有内皮素拮抗剂活性的芳烷烃－磺胺类化合物 Expired - Fee Related CN1326841C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP00/09327 2000-09-25
EP0009327 2000-09-25

Publications (2)

Publication Number Publication Date
CN1633418A CN1633418A (zh) 2005-06-29
CN1326841C true CN1326841C (zh) 2007-07-18

Family

ID=8164105

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB01815896XA Expired - Fee Related CN1326841C (zh) 2000-09-25 2001-08-28 具有内皮素拮抗剂活性的芳烷烃－磺胺类化合物

Country Status (18)

Country Link
US (1) US7091201B2 (https=)
JP (1) JP2004509874A (https=)
KR (1) KR100835770B1 (https=)
CN (1) CN1326841C (https=)
AR (1) AR032896A1 (https=)
AT (1) ATE446289T1 (https=)
AU (2) AU2002212171B2 (https=)
BR (1) BR0114082A (https=)
CA (1) CA2423351C (https=)
DE (1) DE60140263D1 (https=)
ES (1) ES2333409T3 (https=)
HU (1) HUP0303364A3 (https=)
IL (1) IL154364A0 (https=)
MX (1) MXPA03001991A (https=)
NO (1) NO20031332L (https=)
NZ (1) NZ524172A (https=)
WO (1) WO2002024665A1 (https=)
ZA (1) ZA200302292B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
US7482355B2 (en) 2002-08-24 2009-01-27 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
CN1930135B (zh) 2004-03-05 2011-12-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
KR101280095B1 (ko) 2004-08-28 2013-09-09 아스트라제네카 아베 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
CA2619919C (en) 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025900A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
CA2620129C (en) 2005-09-01 2014-12-23 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2012151440A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
CN103864701B (zh) * 2014-03-10 2016-08-24 常熟市金申医化制品有限责任公司 4-磺胺-5-甲氧基-6-氯嘧啶的制备方法
LT3870574T (lt) 2018-10-23 2023-04-11 Step Pharma S.A.S. Aminopirimidino/pirazino dariniai, kaip ctps1 inhibitoriai
EP3980410B1 (en) * 2019-06-04 2025-02-19 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
ES3044436T3 (en) 2019-06-04 2025-11-26 Step Pharma S A S N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1146990A (zh) * 1995-05-16 1997-04-09 田边制药株式会社 氨磺酰衍生物和它的制备方法
EP0882719A1 (en) * 1995-12-20 1998-12-09 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
WO1998057938A1 (en) * 1997-06-19 1998-12-23 Yamanouchi Pharmaceutical Co., Ltd. Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1549494A (https=) 1967-10-31 1968-12-13
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
JP2790065B2 (ja) * 1993-12-17 1998-08-27 田辺製薬株式会社 ベンゼンスルホンアミド誘導体及びその製法
US5837708A (en) * 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
JP3013752B2 (ja) * 1995-05-16 2000-02-28 田辺製薬株式会社 スルホンアミド誘導体
JP3067131B2 (ja) * 1995-06-16 2000-07-17 田辺製薬株式会社 医薬組成物
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物
JPH11343239A (ja) * 1998-03-31 1999-12-14 Tanabe Seiyaku Co Ltd 排尿障害の予防・治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1146990A (zh) * 1995-05-16 1997-04-09 田边制药株式会社 氨磺酰衍生物和它的制备方法
EP0882719A1 (en) * 1995-12-20 1998-12-09 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
WO1998057938A1 (en) * 1997-06-19 1998-12-23 Yamanouchi Pharmaceutical Co., Ltd. Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
ATE446289T1 (de) 2009-11-15
AU2002212171B2 (en) 2006-12-14
ZA200302292B (en) 2004-06-30
MXPA03001991A (es) 2003-06-24
KR100835770B1 (ko) 2008-06-09
US20040102464A1 (en) 2004-05-27
JP2004509874A (ja) 2004-04-02
NZ524172A (en) 2004-09-24
NO20031332D0 (no) 2003-03-24
CA2423351A1 (en) 2002-03-28
WO2002024665A8 (en) 2002-06-06
AU1217102A (en) 2002-04-02
KR20030029979A (ko) 2003-04-16
NO20031332L (no) 2003-03-24
AR032896A1 (es) 2003-12-03
US7091201B2 (en) 2006-08-15
ES2333409T3 (es) 2010-02-22
CA2423351C (en) 2010-12-21
HUP0303364A2 (hu) 2004-03-01
BR0114082A (pt) 2003-07-22
CN1633418A (zh) 2005-06-29
WO2002024665A1 (en) 2002-03-28
DE60140263D1 (de) 2009-12-03
HUP0303364A3 (en) 2004-04-28
IL154364A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
CN100432070C (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1326841C (zh) 具有内皮素拮抗剂活性的芳烷烃－磺胺类化合物
JP4504375B2 (ja) Ｚａｐ−７０および／またはｓｙｋ阻害剤としての２，４−ジ（ヘテロ）−アリールアミノピリミジン誘導体
CZ288030B6 (cs) Sulfonamidové sloučeniny a farmaceutické přípravky na jejich bázi
ES2295048T3 (es) Bis-sulfonamidas.
CN100379730C (zh) 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用
CN100562518C (zh) 芳乙烯磺胺类化合物
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
WO2001081335A1 (en) Pyrimidine-sulfonamides having endothelin-antagonist activity
ES2297040T3 (es) Nuevas alcanosulfonamidas como antagonistas endoteliales.
WO2002083650A1 (en) Novel sulfonylamino-pyrimidines
JP2002138083A (ja) ビススルホンアミド
EP1465875B1 (en) Novel alkansulfonamides as endothelin antagonists
EP1322624A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070718

Termination date: 20120828